Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-1029-3PMID 15073127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• Histopathologic Features of Genetically Determined Ovarian Cancer

  2002cited by this paper
• The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.

  2002cited by this paper
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002influential reference
• Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.

  2001cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations.

  2000cited by this paper
• Primary Ovarian Dysgerminoma in a Patient with a Germline BRCA1 Mutation

  2000cited by this paper
• Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

  1999cited by this paper
• Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.

  1999cited by this paper
• Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours

  1999cited by this paper
• Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.

  1999influential reference
• Toward the development of a universal grading system for ovarian epithelial carcinoma.

  1999cited by this paper
• The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.

  1999cited by this paper
• Clinical and genetic evaluation of thirty ovarian cancer families.

  1998cited by this paper
• Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.

  1998cited by this paper
• Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

  1998cited by this paper
• Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.

  1998cited by this paper
• Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.

  1998cited by this paper
• Frequency of germline and somatic BRCA1 mutations in ovarian cancer.

  1998influential reference
• Toward the development of a universal grading system for ovarian epithelial carcinoma

  1998cited by this paper
• Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.

  1997cited by this paper
• Contribution of BRCA1 mutations to ovarian cancer.

  1997influential reference
• Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases

  1997cited by this paper
• Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.

  1996influential reference
• Observer disagreement in histological classification of ovarian tumors in Japan.

  1994cited by this paper
• Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications

  1991cited by this paper
• Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology.

  1987cited by this paper
• The behavior of maximum likelihood estimates under nonstandard conditions

  1967cited by this paper

• BRCA1 and BRCA2 in DNA damage and replication stress response: Insights into their functions, mechanisms, and implications for cancer treatment.

  2025cites this paper
• Predictive biomarkers for targeted therapy in daily anatomic pathology for ovarian tumors

  2025cites this paper
• Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers

  2025cites this paper
• Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer

  2025cites this paper
• Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies

  2024cites this paper
• Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk

  2024cites this paper
• Gynecologic and breast cancers with hereditary cancer predisposition syndromes

  2024cites this paper
• Whole genome and transcriptome analysis of pancreatic acinar cell carcinoma elucidates mechanisms of homologous recombination deficiency and unravels novel relevant fusion events.

  2024cites this paper
• An Analysis of Genetic Polymorphisms in 76 Genes Related to the Development of Ovarian Tumors of Different Aggressiveness

  2024cites this paper
• Current Understanding of the Epidemiology and Clinical Implications of BRCA1 and BRCA2 Mutations for Epithelial Ovarian Cancer

  2024cites this paper
• A model and multi-core parallel co-evolution algorithm for identifying cancer driver pathways

  2024cites this paper
• Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk‐reducing surgical decision‐making practices: A mixed‐methods study

  2023cites this paper
• Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

  2023cites this paper
• Physiological Pathway, Diagnosis and Nanotechnology Based Treatment Strategies for Ovarian Cancer: A Review

  2023cites this paper
• A nonlinear model and an algorithm for identifying cancer driver pathways

  2022cites this paper
• Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta‐analysis

  2022cites this paper
• Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial

  2022cites this paper
• Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants

  2022cites this paper
• BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers

  2022cites this paper
• Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment

  2021cites this paper
• First‐ and second‐degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and white women

  2021cites this paper
• Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers

  2021cites this paper
• The Effect of deinoxanthin Isolated from Radioactivity-Resistant Bacteria on Expression of Bcl-2 Gene in Hela Cell Line

  2021cites this paper
• The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence

  2021cites this paper
• Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review)

  2021influential citation
• Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Biomarkers and Strategies for Early Detection of Ovarian Cancer

  2020cites this paper
• HRness in Breast and Ovarian Cancers

  2020influential citation
• Second Primary Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers after Breast Cancer Diagnosis: Korea Central Cancer Registry

  2020cites this paper
• Pathology of Hereditary Breast and Ovarian Cancer

  2020cites this paper
• The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene

  2020cites this paper
• Non-invasive Technology Advances in Cancer—A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers

  2020influential citation
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021

  2020cites this paper
• Clinical significance of combining salivary mRNAs and carcinoembryonic antigen for ovarian cancer detection

  2020cites this paper
• Managing a woman with BRCA mutations? Shared decision-making is key.

  2020cites this paper
• CEBP FOCUS Biomarkers and Strategies for Early Detection of Ovarian Cancer

  2020cites this paper
• Carcinoma of the Ovaries and Fallopian Tubes

  2020cites this paper
• Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

  2020cites this paper
• Çanakkale İlimizdeki Jinekolojik Kanserlerde Yeni Nesil DNA Dizi Analizi ile Saptanan Mutasyon Profilleri

  2020cites this paper
• Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer

  2020cites this paper
• A profile on the FoundationFocus CDxBRCA tests

  2020cites this paper
• Clinical and histopathologic analysis of gynecological cancer: a single institute experience over 7 years

  2020cites this paper
• Tumor Microenvironment

  2020cites this paper
• Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer.

  2020cites this paper
• Effect of BRCA1 and BRCA2 mutations on endometrial carcinoma survival rates

  2020influential citation
• The Immune Landscape in Women Cancers.

  2020cites this paper
• The use of tamoxifen in the treatment and prevention of breast cancer

  2019cites this paper
• The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.

  2019cites this paper
• Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2019cites this paper
• Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.

  2019cites this paper
• The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance

  2019cites this paper
• Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

  2019cites this paper
• Hereditary ovarian cancers: state of the art.

  2019cites this paper
• Prise en charge gynécologique des patientes mutées BRCA1/BRCA2 indemnes de cancer par les gynécologues de Picardie

  2019cites this paper
• Polymorphism of DNA Repair Genes via Homologous Recombination (HR) in Ovarian Cancer

  2019cites this paper
• Clinicoepidemilogical Correlation of BRCA 1 and 2 Mutations in Carcinoma Ovary - an Indian Perspective

  2019cites this paper
• Management of Gynecologic Cancers In Relation to Genetic Predisposition.

  2019cites this paper
• Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.

  2019cites this paper
• The precision medicine approach to cancer therapy: part 1 — solid tumours

  2019cites this paper
• The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer

  2019cites this paper
• UČINKOVITOST I PODNOŠLJIVOST KEMOTERAPIJE PO TC PROTOKOLU VEĆE GUSTOĆE U PRVOLINIJSKOM LIJEČENJU KARCINOMA JAJNIKA

  2019influential citation
• Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision

  2018cites this paper
• The Chemoprevention of Ovarian Cancer: the Need and the Options

  2018cites this paper
• Over Kanseri Perspektifinde BRCA Gen Mutasyonları Ve Herediter Meme ve Over Kanser Sendromu

  2018cites this paper
• Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.

  2018cites this paper
• BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study

  2018cites this paper
• Familial Ovarian Cancer Clusters with Other Cancers

  2018cites this paper
• Communication about genetic testing and hereditary cancer management with breast and ovarian cancer patients

  2018cites this paper
• Personalized prevention in high risk individuals: Managing hormones and beyond.

  2018cites this paper
• Microfluidic platforms for rapid screening of cancer affinity reagents by using tissue samples.

  2018cites this paper
• Familial risks of second primary cancers and mortality in ovarian cancer patients

  2018cites this paper
• Population masculine au sein des familles avec mutation germinale dans les gènes BRCA1 et BRCA2 aspects cliniques et pathologiques des cancers

  2018cites this paper
• Defective DNA repair in hereditary ovarian cancers: Implications for therapy

  2018cites this paper
• Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature

  2018cites this paper
• Familial risks of ovarian cancer by age at diagnosis, proband type and histology

  2018cites this paper
• Clear cell carcinomas of the ovary and kidney: clarity through genomics

  2018cites this paper
• Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review

  2018cites this paper
• ASPECTOS REPRODUCTIVOS EN MUJERES PORTADORAS DE MUTACIONES GENÉTICAS BRCA

  2017cites this paper
• Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene

  2017cites this paper
• BMI-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death.

  2017cites this paper
• BRCA mutations in the manifestation and treatment of ovarian cancer

  2017cites this paper
• Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.

  2017cites this paper
• BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype

  2017cites this paper
• Missed therapeutic and prevention opportunities in women with BRCA‐mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature

  2017cites this paper
• Lifestyle and Reproductive Factors and Ovarian Cancer Risk by p53 and MAPK Expression

  2017influential citation
• Genetics of Ovarian Carcinomas

  2017cites this paper
• Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents

  2017cites this paper
• Frontiers in Ovarian Cancer Science

  2017cites this paper
• Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers

  2017cites this paper
• Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age

  2017cites this paper
• BRCA mutations in the manifestation and treatment of ovarian cancer.

  2017cites this paper
• The Prevalence And Clinical Significance Of Mutations BRIP 1 , BARD 1 , PALB 2 And NBN Genes In Women With Ovarian Cancer

  2017cites this paper
• Loss of rad51 in zebrafish (Danio rerio) : a novel Fanconi anaemia model

  2017cites this paper
• Hereditary Ovarian Cancer and Risk Reduction.

  2017cites this paper
• Epidemiology of ovarian cancer: a review

  2017cites this paper
• Hereditary Ovarian Cancer

  2017cites this paper
• Pelvic high-grade serous carcinoma in BRCA 1 and BRCA 2 mutation carriers Reitsma

  2017cites this paper
• Clinical Management Guidelines for Obstetrician – Gynecologists Background BRCA 1 and BRCA 2 Germline

  2017cites this paper
• The identification of novel strategies for the prevention and treatment of breast cancer in BRCA1-mutation carriers

  2016cites this paper
• Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.

  2016cites this paper